Journal article
Palivizumab in congenital heart disease: should international guidelines be revised?
Expert opinion on biological therapy, Vol.7(11), pp.1615-1620
11/01/2007
DOI: 10.1517/14712598.7.11.1615
PMID: 17961086
Abstract
Palivizumab has reduced the incidence of respiratory syncytial virus hospitalization in infants and children with congenital heart disease by 45%. Although the mortality rate of children with congenital heart disease hospitalized with respiratory syncytial virus infection has declined from 37% to ∼ 3% over the past 3 decades, palivizumab has not been shown to improve mortality. There has been considerable controversy over the cost-effectiveness of administering palivizumab according to international guidelines, including children with congenital heart disease. In particular, the number of children that need to be treated with palivizumab to prevent one respiratory syncytial virus hospitalization increases dramatically in children > 12 months of age. As a result, the authors recommend that countries re-examine their recommendations for providing palivizumab up to age 24 months in children with congenital heart disease.
Details
- Title: Subtitle
- Palivizumab in congenital heart disease: should international guidelines be revised?
- Creators
- Joseph M Geskey - Pennsylvania State UniversityNeal J Thomas - Penn State Milton S. Hershey Medical CenterGretchen L Brummel - Penn State Milton S. Hershey Medical Center
- Resource Type
- Journal article
- Publication Details
- Expert opinion on biological therapy, Vol.7(11), pp.1615-1620
- Publisher
- Informa UK Ltd
- DOI
- 10.1517/14712598.7.11.1615
- PMID
- 17961086
- ISSN
- 1471-2598
- eISSN
- 1744-7682
- Number of pages
- 6
- Language
- English
- Date published
- 11/01/2007
- Academic Unit
- Pharmacy Practice and Science
- Record Identifier
- 9984772258202771
Metrics
3 Record Views